Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Gross margin
€ 2.4 million
▲ 69% vs 2023
Profit
Caution€ -11.8 million
▼ 10% vs 2023
Debts
Low€ 3.6 million
▼ 67% vs 2023
Ziphius from Gent, company number BE0750500975, closed financial year 2025 with a result of € -11.8 million after tax. For that financial year Ziphius recorded a gross margin of € 2.4 million and equity of € 5.9 million. Compared with financial year 2023, the result moved from € -10.7 million to € -11.8 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 26, 2026.
What happened at Ziphius?
What happened at Ziphius in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Margareta Nuytinck stepped down as director. NBB
- Van Hoof Biotech and Business Services BV stepped down as director. NBB
- JOB.BIO.COM BV stepped down as director. NBB
- Olem SRL stepped down as director. NBB
- Geertrui Vanhove stepped down as director. NBB
- CARDON BIO NV stepped down as director. NBB
- Heran BV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 11.8 million. Source: NBB ↗
In short
From € 3.8 million loss in 2021 to € 11.8 million loss in 2025.
Paid € 2,199 in corporate taxes since 2021.
On average € 59,000 of value added per employee in 2025.
A new publication or filing at Ziphius? We notify you, reason included.
Follow ZiphiusNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Margareta Nuytinck
Director
Also active at: LABORATORIUM M. NUYTINCK, QUOD BONUM, FELIX FAUSTUMQUE SIT, LABO VOOR KLINISCHE BIOLOGIE +4 more
since 2024 · until 2030
Van Hoof Biotech and Business Services BV
Director · represented by Johan Van Hoof
since 2023 · until 2027
Director · represented by Johan Bury
since 2024 · until 2027
Director · represented by Olivier Lemaire
since 2021 · until 2027
Geertrui Vanhove
Director
since 2024 · until 2027
Managing director · represented by Christiaan Cardon
since 2024 · until 2027
Establishments
Establishment units
Physical locations of this company
Rijvisschestraat 120
9052 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
RNA Pioneering
€ -111,461 gross margin · 2025
DOING WELL BY DOING GOOD
€ 27,550 gross margin · 2025
CARDON BIO same network
€ 25,626 gross margin · 2025
CELL-CELL BIO
€ 777,487 gross margin · 2025
BORDEAUX I
€ -3,685 gross margin · 2025
+1 more
Details
- Company number
- 0750.500.975
- VAT number
- BE 0750.500.975
- Registered office
- Rijvisschestraat 120, 9052 Gent
- Names & denominations
- Ziphius
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 July 2020
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van geneesmiddelen